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1 Abstract
Macrophages (M $ ’s) play an essential role in immunity through their sensing and 
activation by different environmental signals. When stimulated with Interferon 
gamma (IFN7 ) and Toll Like Receptor (TLR) ligands, M $ ’s are activated to a 
Classical, or M l, phenotype, characterized by anti-microbial activity and produc­
tion of pro-inflammatory cytokines. Stimulation with chitin, Interleukin-4 (IL-4), 
or IL-13 polarizes M $ ’s to an alternative, wound healing phenotype, important 
for restoration of the extracellular matrix upon tissue damage. Here I showed that 
alternatively activated (AA) M $ ’s can be polarized upon stimulation with IFN7 
and the TLR ligand, lipopolysaccharide (LPS) to a classically activated (CA) phe­
notype. This conversion from an AA to CA phenotype is further shown to progress 
through a hybrid CA-AA period. However, CA-M $’s are less plastic, showing no 
conversion to an AA phenotype upon stimulation with IL-4. I further examined 
the effects of Toxoplasma gondii infection on M $ activation pathways. Type I 
ROP16 was found to be essential for the induction of an AA phenotype but not 
necessary for the expression of Th2 promoting chemokines. Furthermore, T. gondii 
pre-infected cells retain the ability to be polarized to an AA phenotype upon IL-4 
treatment. Together, these results suggest that in contrast to the canonical clas­
sification of T. gondii as a Thl pathogen, T. gondii infection of MT’s puts it in a 
versatile position to elicit and control both a host Thl and Th2 response.
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2 Introduction
Macrophages (M $) comprise a heterogeneous population of cells that play a piv­
otal role in the control of the innate response to pathogens. While the role of 
M $ ’s in the immune system has long been known and studied, recent advances 
in our understanding of M<f> biology have shown their importance extends to such 
processes as tissue homeostasis, wound repair, and development. Therefore, while 
studying M<f> biology has far-reaching effects on our understanding of immunity, 
so too must our focus evolve to account for the growing diversity of M $ functions.
2.1  M acroph age B iology
A complete picture of monocyte development and heterogeneity remains incom­
plete, but the mononuclear phagocyte system (MPS), proposed and later refined 
by Van Furth et ah, 1972, remains widely accepted [1]. Macrophage development 
begins in the bone marrow where hematopoietic stem cells develop into granulo- 
cyte/macrophage colony-forming units (GM-CFU), a common myeloid progenitor 
cell, in a macrophage colony-stimulating factor 1 (CSF1) dependent fashion [2, 3]. 
These neutrophil-M$ cell precursors further differentiate into monoblasts and then 
pro-monocytes which then exit the bone marrow and enter the blood stream before 
differentiating into monocytes [4],
Monocytes are further divided based on chemokine receptor expression patterns 
and the presence of specific cell surface markers. Inflammatory monocytes are char­
acterized by expression of high levels of the surface molecule LY6C (G rl+), high 
levels of the CC-chemokine receptor 2 (CCR2) and low levels of CX3C-chemokine 
receptor 1 (CX3CR1). These monocytes, as their name suggests, are rapidly re-
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cruited to sites of inflammation in a CC-chemokine ligand 2 (CCL2) dependent 
manner [2, 5]. Following infection, these monocytes can readily differentiate into 
inflammatory dendritic cells (DC), TNFa/iNOS expressing dendritic cells (Tip- 
DCs), or classically activated macrophages (CA-M $’s) [5, 6].
However, in the absence of inflammation, CCR2+ CX3CR1low LY6Chlgh mono­
cytes have been shown to pass through a LY6Cmid phenotype before returning 
to the bone marrow and differentiating into resident or tissue monocytes. These 
monocytes, characterized by low levels of CCR2 and high levels of CX3CR1, can 
travel along the lumen of small blood vessels in a process called patrolling and 
enter non-inflamed tissues. As these monocytes readily reside in tissue, upon in­
fection, these monocytes will rapidly respond by producing different chemokines 
and cytokines, which in turn, help in the recruitment of inflammatory monocytes
[5, 7].
2.2  T h e R ole o f M acrophages in Innate Im m u n ity
As professional phagocytes, M $ ’s express a number of different pattern-recognition 
receptors (PRR) used to recognize different signs of infection. These PRRs include 
Toll-like receptors (TLRs), NOD-like receptors (NLRs), Retinoid acid-inducible 
gene I (RIG-1) like receptors (RLRs), C-type Lectin receptors (CLRs), and a num­
ber of different scavenger receptors. These different receptor families have evolved 
to detect specific pathogen-associated molecular patterns (PAMPs)— conserved 
microbial structures— and endogenous danger signals, such as signs of apoptosis. 
The interaction between PRRs and their respective ligands provides key informa­
tion to the M $ ’s, indicating the location and type of infection, and also determines
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the appropriate response needed to clear the pathogen [8, 9, 10].
The TLRs in particular, have received considerable study because of the major 
role these receptors play in recognition of both extracellular and intracellular sig­
nals. Of the 13 TLRs identified in mice, TLR4, which binds to Lipoplysaccharide 
(LPS), is of particular relevance to my work because signaling through TLR4 is 
necessary for classical activation of MT’s. TLR4 signaling has been divided into 
two signal transduction pathways: a MyD88 dependent; and a MyD88 independent 
pathway [11].
The MyD88-dependent response to LPS begins with stimulation of IL-1 receptor- 
associated kinase-4 (IRAK-4). IRAK-4 activation leads to activation of TRAF6 
(TNFa receptor-associated factor 6), which in turn, complexes with UBC13 (ubiquitin- 
conjugating enzyme 13) and UEV1A (ubiquitin-conjugating enzyme E2 variant 1 
isoform A) to activate TAK1 (transforming growth factor /? activated kinase 1). 
TAK1 activation leads to downstream activation of the transcription factor NF-kB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) which, along with 
MAPK (mitogen activated protein kinase) induced AP-1, leads to expression of 
pro-inflammatory cytokines (Fig. 1) [11].
The MyD88-independent pathway also signals through the NF-kB pathway but 
acts through TRIF (Toll-interleukin-1 receptor containing adaptor protein) which 
signals through TRAF3 (TNF receptor-associated factor 3 ) and the transcription 
factor IRF3 (Interferon Regulatory Factor 3). TRIF also signals through RIP1 to 
activate MAPK and NF-kB pathways. Signaling through this MyD88-independent 
pathway leads to production of Type I interferons (Fig. 1) [11].
In considering the biological events that lead to inflammation, the first cells to 
respond at a site of injury or infection are resident macrophages and mast cells
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Figure 1: MyD88-dependent and MyD88-independent TLR4 signal transduction.
which, triggered by different PRR-PAMP interactions, begin the process of leuko­
cyte recruitment through the release of chemokines, cytokines, and other products. 
Modification of local epithelium allows the influx of neutrophils, which extravasate 
into the site of infection, phagocytose invading pathogens, and release the damag­
ing contents of their granules into the microenvironment. Additional leukocytes 
continue to be recruited, including monocyte-derived Tip-DCs and M $ ’s, both of 
which act as phagocytes and as potent microbicidal agents [10].
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Eventually however, inflammation must be resolved. Not only is the release 
of reactive oxygen species (ROS) and reactive nitrogen species (RNS) damaging 
to surrounding tissues, but active removal of dead neutrophils and cellular debris 
is necessary for the tissue to return to normal as failure to clear apoptotic cells 
can lead to continued aggravation of inflammation. It is here that the importance 
of M $ ’s as janitorial cells shine. The expression of different scavenger receptors, 
phosphatidyl serine receptors, and complement receptors— to name a few— allows 
M $ ’s to recognize such endogenous danger signals as heat shock proteins, extra­
cellular ATP, histones, DNA, and other byproducts of apoptosis. Understanding 
of these apoptosis-cell-associated molecular patterns (ACAMPs) carries however, 
a whole host of other complexities; namely, that PRR engagement by ACAMPs 
must carry some distinguishing factor different from engagement with PAMPs. 
CD 14 for example, which mediates transfer of LPS to TLR4 and the induction of 
a pro-inflammatory response has also been shown to be important for recognition 
of ACAMPs containing LPS-like structures [11]. However, signaling of ACAMPs 
by CD 14, as with other ACAMPs, leads to an anti-inflammatory response. Inges­
tion of these molecules changes the macrophage phenotype. Several hypotheses 
to explain this phenomenon have been proposed including (i.) formation of CD14 
with receptors other than TLR4 and (ii.) that anti-inflammatory pathways over­
ride pro-inflammatory signaling [12].
2 .3  T h e R ole o f  M acrophages in A d ap tive  Im m u n ity
In addition to their roles in Innate Immunity, M $ ’s also play an important role 
in activation of the Adaptive Immune system. While M T’s readily respond to
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early stimuli at the site of infection, they are also subject to signals from antigen- 
primed immune cells. In particular, M T’s have been classified into different ac­
tivation states in a manner, similar to the nomenclature in T-cell literature: Ml 
M T’s, the classically activated innate activated M $ ’s, are characterized by high 
levels of pro-inflammatory cytokines and microbicidal activity; M2 macrophages 
on the other hand, represent an umbrella of different activation states, including 
the alternatively activated and regulatory/deactivating M $ ’s (Table 1).
2.3.1 Classical Activation of Macrophages
Classically activated macrophages (CA-M<f>) are the best-documented of the dif­
ferent M<1> activations. Priming of M $ ’s with Interferon-7 (IFN7 ) followed by 
stimulation with Tumor Necrosis Factor (TNFa) or TLR ligands results in M T’s 
vital to host defense due to their secretion of pro-inflammatory cytokines and mi­
crobial killing [2]. While an important source of early IFN7  comes from Natural 
Killer (NK) cells, production of IFN7  by these innate cells is not sustained. There­
fore, in order for continued classical activation of MT’s, an antigen specific Thl 
response must be induced. Subsequent TLR activation can result from direct con­
tact of primed M $ ’s with TLR ligands— such as LPS— or from TNFa, produced 
by antigen presenting-cells (APCs) in a TLR-MyD88 dependent signaling cascade.
These CA-M $’s show enhanced microbicidal activity due to their increased 
production of superoxide anions (02 ') and induction of iNOS (inducible nitric 
oxide synthase), an enzyme that catalyzes L-arginine-dependent production of 
microbicidal nitric oxide molecules (NO) [2], Xia and Zweier, 1997, showed that in 
L-arginine depleted M $ ’s, iNOS mediates production of superoxide anions which 
in turn, react with NO to form potent peroxynitrite species (ONOO"); these potent
oxidizing species can degrade microbial cell membranes [13]. NO cytotoxicity can 
also occur through deamination of DNA bases, leading to widespread mutations, as 
well as inhibit the activity of enzymes containing iron-sulfur centers [14]. Together, 
these cytotoxic effects of NO render it an essential molecule for host protection 
against parasitic and microbial infections [14].
CA-MT’s also upregulate production of the pro-inflammatory cytokines Interleukin- 
1/3 (IL-1), IL-6, IL-12, and IL-23. IL-12 acts in a positive feedback loop, promoting 
the differentiation of Thl cells which, under the influence of IL-12, secrete increased 
levels of IFNy and TNFa. CA-MT’s have also been shown to promote differentia­
tion of Thl7 cells through secreted IL-1, IL-6, and IL-23. These Thl7 cells secrete 
high levels of IL-17 which in turn, exacerbate the inflammatory response through 
recruitment of granulocyte populations [1]. CA-M $’s have also been shown to 
express increased levels of Major Histocompatability Complex (MHC) Class II 
and B7 co-stimulatory molecules (CD86) which enhances their ability to drive a 
primary T-cell response [15].
Expression of markers of CA is controlled at several levels by different transcrip­
tion factors, phosphorylation cascades, and transcription regulators. IFN7  signal­
ing through the Janus-kinase (JAK) Mitogen activated protein-kinase (MAPK) 
signaling cascade results in phosphorylation and dimerization of the transcription 
factor STAT1 (signal transducer and activator of transcription 1). Phosphory- 
lated STAT1 is then imported into the nucleus where it binds as a homodimer to 
gamma-activated sequences, including the promoters of Nos2 and IL-12, and in­
duces expression. Interferon Regulatory Factor 5 (IRF5) has recently been shown 
to play a role in CA; IRF5 is required for maximum pro-inflammatory cytokine 
production and is now thought to participate with other transcription factors, such
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as RelA, to induce classical gene expression while inhibiting transcription of A A 
markers and IL-10 [16].
The response of CA-MT’s to pathogens has been well documented. In mice 
lacking IFN7  expression, an increased vulnerability to viral, bacterial, and proto­
zoan infection is seen [2,4], For many intracellular pathogens, impairment of these 
CA pathways is essential for its continued survival within its host. For exam­
ple, studies of Mycobacterium tuberculosis-induced deactivation have implicated 
lipoarabinomannan (LAM), a glycolipid, in the interference of IFN7  signaling and 
attenuation of M $ responses to TNFa and LPS. Similarly, work with Leishma- 
nia spp. has shown that attempts to activate M $ ’s after infection are thwarted 
because infection disrupts or redirects IFN7  signaling in M $ ’s [2].
Clearance of Leishmania spp. is dependent on induction of a robust CA-MT 
population. Whereas IFN7  treatment alone results in inefficient clearing of para­
site, stimulation of M $ ’s with IFN7  and TNFa before infection results in complete 
clearance of the parasite; similar parasite killing is observed upon IFN7  and LPS 
stimulation [2],
2.3.2 Alternatively Activated Macrophages
Stimulation with IL-4 or IL-13 on the other hand, polarizes M $ ’s to an alter­
natively activated (AA) phenotype [2, 15]. IL-4 production can arise from the 
adaptive immune response via Th2 cells or from granulocytes of the innate im­
mune response. AA can also occur when M $ ’s come in response to contact with 
chitin and helminth infection [2, 3].
AA-M T’s, or wound-healing M $ ’s as they are commonly called, show markedly 
different expression patterns and phenotype compared to the CA-M $’s. AA-
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M $ ’s are characterized by increased expression of Arginase 1 (Argl), mannose 
receptor (CD206), CCL17 (Chemokine (C-C motif) Ligand 17), Ym l and Ym2—  
two chitinase-like molecules— and FIZZl/RELM a—found in inflammatory zone 
1/resistin-like molecule alpha [2, 15, 17].
AA-M<f>’s are controlled at the transcription level by several different signaling 
axes. IL-4 signals through the IL-4 receptor-a (IL-4Ra), which in turn signals 
through a JAK-STAT6, pathway and activates other signaling molecules such as 
phosphoinositide 3-kinase (PI3K). Whereas CA markers are until the control of 
STAT1, AA markers are under the control of STAT6. Expression of A A mark­
ers can also occur through the C/EBP family of transcription factors. However, 
whereas STAT6 mediates expression of genes such as Argl in response to IL-4, 
the cAMP-responsible element-binding-protein (CREB)-C/EBP/3 axis regulates 
the induction of Argl in response to TLR stimulation. Additionally, the CREB- 
C/EBP (3 may also play a role in the downregulation of CA activation by inducing 
the expression of dual specificity protein phosphatase 1 (DUSP1), which inhibits 
expression of pro-inflammatory genes [3].
A A -M $’s have been shown to be necessary for protection and clearance of 
helminth infection. Schistosoma mansoni infection and subsequent egg deposition 
is dominated by a Th2 response while Thl responses are downregulated. Because 
a robust Th2 response increases the granuloma response to parasite eggs, AA- 
M $ ’s can be thought of as detrimental. However, infected IL4"/" mice fail to 
stimulate a Th2 response and eventually die, indicating the necessity of a Th2 
response in host protection. Satoh et ah, 2010, showed that the Jumonji domain 
containing-3 (JMJD3) histone 3 Lys27 (H3K27) demethylase is required for AA 
in response to helminth infection and chitin [18], JMJD3"/" mice are unable to
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upregulate a strong Th2 response upon infection with Nippostrongylus brasiliensisi, 
a potent Th2 inducer [18]. One such target of JMJD3 activation is the Interferon 
Regulatory 4 (IRF4) transcription factor promoter region; Irf4~/~ mice are unable 
to upregulate AA markers after chitin stimulation. It is thought that this JMJD3 
axis acts independently of IL-4 signaling and responds instead to stimulation by 
chitin. However, the details of chitin signaling and the PRRs associated with 
helminth recognition are still unknown [3, 18, 19].
While AA-M T’s are essential for immunity against helminths, polarization of 
AA-M T’s can also increase susceptibility to intracellular pathogens [2], This may 
be due in part to notably different metabolism patterns of L-arginine in AA-M T’s. 
Whereas in CA-MT's, L-arginine is rapidly catabolized by iNOS, AA-M T’s ex­
press high levels of Argl which converts arginine to ornithine [2-4], Ornithine 
can be acted on by ornithine amino-transferase (OAT), which leads to increased 
production of proline, a necessary building block of collagen. Ornithine can also 
be decarboxylated into putrescine by orinithine decarboxylase (ODC); putrescine, 
through the activity of spermine and spermidine synthase, is converted to sper­
mine and spermidine respectively. Recently it has been shown that polyamines 
such as putrescine, spermine, and spermidine, may play a role in induction of cer­
tain AA-markers, including Ym l and FIZZ1; other AA markers, like Argl, are 
readily induced independently of polyamines. Additionally, polyamine-depleted 
M $ populations have higher levels of pro-inflammatory gene expression but not 
enhanced secretion levels indicating they may play a role in maintaining an AA 
phenotype [4], In the context of L. major infection, this sustained Argl activ­
ity contributes to pathology; inhibition of Argl is thought to decrease parasite 
viability by limiting the availability of polyamines [20].
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Table 1: Characteristics and biomarkers of activated M<f> populations.
IFN7 : Interferon-gamma; TNF: Tumor Necrosis Factor; TLR: Toll-like Re­
ceptor; IL: Interleukin; MHC-II: Major Histocompatibility Complex II; iNOS: 
inducible Nitric Oxide Synthase; FIZZ1: found in inflammatory zone 1; CCL: 
CC-chemokine ligand; Argl: Arginase-1 SPHK1: sphingosine kinase 1; LIGHT: 
homologous to lymphotoxins, shows inducible expression and competes with 
herpes simplex virus glycoprotein D for herpes virus entry mediator (HVEM) on 
T-cells
2.3.3 Regulatory Macrophages
Regulatory Macrophages (R-MT) are the least well characterized of the estab­
lished M<F activations. First discovered by Gerber and Mosser, 2001, these M $ 
can be activated by a number of different signals. Generally, the first signal is an 
anti-inflammatory signal. This can come in the form of prostaglandins, adenosine, 
immune complexes, IL-10, or apoptotic cells; glucocorticoids for example, are se­
creted by adrenal cells under stress conditions and can act as a primary stimulant.
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The second required signal is a TLR ligand; the combination of these two signals 
generates a M $ population characterized by high IL-10 production and low IL-12
secretion [2, 15].
Before the discovery and subsequent characterization undertaken by Mosser’s 
group, R-M T’s have often been confused with AA-M T’s. This is a mistake as 
R -M $’s have both a unique phenotype and role in immunity. R-MTs do not 
contribute to the extracellular matrix, express little to no Argl, Ym l, and FIZZ1, 
and signaling in R -M $’s does not depend on STAT6; AA-M T’s can secrete IL- 
10 when stimulated by IL-4 and LPS, but only a modest increase is observed. 
Interestingly, these R -M $’s also produce high levels of co-stimulatory molecules 
CD80 and CD86 and co-culturing experiments have been shown R- M T’s to be the 
most effective, when compared with CA and AA-MT populations, at activating 
nave T-cell populations. Therefore, despite their anti-inflammatory phenotype, R- 
M $ ’s continue to be potent APCs; furthermore, due to their production of IL-10, 
R -M $’s can induce the expansion of Th2 cells, which in turn, secrete IL-4 and 
IL-13, amplifying the A A of M $ ’s [2, 15].
There is a continued need to identify the signaling pathways that lead to R- 
M T’s. While the MAPK Extracellular signal-regulated kinase (ERK) axis has 
been implicated, not all ERK stimulation results in IL-10 production from M Ps. 
Additional characterization of R-MT’s is also needed in order to identify distinct 
biomarkers. SPHK1 (sphingosine kinase-1) and LIGHT (Tumor necrosis factor 
ligand superfamily member 14) were recently identified by Edwards et al., 2006. 
How these markers complement the current anti-inflammatory profile of ll-M 'ks 
is not completely understood but LIGHT may contribute to the effectiveness of 
R-M $ mediated T-cell activation and SPHK1, to the control of pro-inflammatory
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cytokine production [2, 15].
Due to their anti-inflammatory phenotype, R-M T’s may be exploited by pathogens. 
Leishmania spp. amastigotes are coated with host IgG, which engages M $ Fc re­
ceptors for IgG (FcyR) upon entry. Similarly, African trypanasomes, through the 
constant shifting of their surface antigens, induce a strong antibody response and 
generation of immune complexes. These immune complexes too can bind to M $ 
Fey R and produce anti-inflammatory IL-10 production [2, 15]. Therefore, there 
is a growing need to better understand and characterize these therapeutically rel­
evant M $ population.
2.3.4 Plasticity of Macrophage Activation
Unlike cells of the adaptive immune system, which undergo extensive epigenetic 
modifications during their differentiation, the M<f> landscape remains plastic, al­
lowing them to respond to different environmental cues [2]. One example of this 
shift in phenotype is observed during long-term exposure to LPS. Endotoxin tol­
erance is the progressive attenuation of pro-inflammatory responses after repeated 
or sustained LPS stimulation. What is interesting about endotoxin tolerance is 
that different genes are affected in different ways. Whereas, pro-inflammatory gene 
expression is reduced, anti-inflammatory and anti-microbial genes continue to be 
readily inducible [3].
If we consider a typical inflammatory response, CA-MT’s dominate the in­
flamed tissues and play an important role in the initial response and subsequent 
clearance of a pathogen at the site of infection. Eventually, this CA-MT population 
is replaced by A A -M $’s so that tissue damage and wound-healing can be initiated. 
What is unclear however, is whether this anti-inflammatory population is the re-
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suit of a shift in gene expression— namely, that these M T’s arise from the original 
classically activated population— or if this population results from the subsequent 
migration and replacement by anti-inflammatory M T’s from the blood. A caveat 
of this latter model is that migration or apoptosis of the original Md> population 
must occur in order for an anti-inflammatory landscape to dominate the tissue. 
These two models are not mutually exclusive as monocyte populations in tissues 
are constantly replenished, but the growing literature on this topic suggests that 
MT's can undergo a transcriptional reprogramming at the onset of inflammation 
[2] -
Work done by Stout et ah, 2005, has often been cited as evidence of this 
genetic reprogramming. Stout et al. sequentially treated bone marrow derived 
macrophages (BMMT) with different cytokines and LPS in order to identify a 
shift in cytokine profile. Stout et al. conclude that the functional phenotype of 
M $ ’s— that is, their pro-inflammatory or anti-inflammatory phenotype— can shift 
as the microenvironment is changed; pro-inflammatory M l ’s produce lower levels 
of pro-inflammatory cytokines IL-12, TNFa, and IL-6 upon IL-10 treatment. Simi­
larly, IL-4 treated M l ’s can shift to become potent producers of pro-inflammatory 
cytokines upon LPS or IFNy/LPS treatment [21].
There are however, shortcomings to this study. First, because of the time scale 
investigated, only M $ phenotypes at the initiation and endpoint of treatment are 
examined. What this fails to answer, is whether this shift in phenotype is a direct 
from a pro to anti-inflammatory phenotype or whether M l ’s return to a state 
of deactivation or navet (neither pro-inflammatory or anti-inflammatory) before 
becoming re-polarized. Because Stout et al. only measured pro-inflammatory 
cytokine profiles, no information is given about the anti-inflammatory profile of
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these M T’s; it is possible that sequential treatment of M<f> populations can result in 
a hybrid anti-pro-inflammatory population. Similarly, Stout et al. only examined 
the impacts of IL-10 on attenuation of pro-inflammatory signaling. This fails to 
address the effects of IL-4 stimulation of pro-inflammatory M $ populations.
I examined the changes in gene expression of CA-MT’s following IL-4 treat­
ment for a number of timepoints; the opposite scheme— stimulation of AA with 
CA polarizing IFN7 /LPS— was examined as well. My Reverse Transcriptase- 
Quantitative Polymerase Chain Reaction (RT-qPCR) data shows that rather than 
return to a state of deactivation, MT’s can display a hybrid pattern of gene ex­
pression, upregulating both CA and AA markers. Lastly, my examination of CA 
and AA gene expression profiles indicates that there is a differential underlying 
plasticity associated with classical and alternatively activated M $ ’s.
2 .4  Toxoplasma gondii
Toxoplasma gondii is an obligate intracellular parasite and member of the phylum 
Apicomplexa that infects anywhere from a third to eighty percent of the popu­
lation in select geographic locations [22, 23]. T. gondii’s prevalence throughout 
the human population is a testament to its well-studied ability to manage and 
balance the immune system of its host; because Toxoplasma is such a master ma­
nipulator of immune system, it has become a model for the study of host-pathogen 
interactions.
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2.4.1 Life Cycle and Clinical Importance
Transmission of Toxoplasma begins with ingestion of cysts in undercooked meat or 
by accidental ingestion of food or water contaminated with oocysts from cat feces. 
After ingestion, Toxoplasma rapidly replicates and differentiates into tachyzoites 
within the digestive tract of the host. These tachyzoites cross the gut epithelium 
and disseminate throughout the host [22, 23, 24], During this acute phase of in­
fection, Toxoplasma can invade all nucleated cells and this widespread replication, 
dissemination, and subsequent tissue damage induces a Thl response character­
ized by high levels of IL-12, TNF, and IFNq, vital for parasite control [25] It is 
around this time that under pressure from the host immune system, tachyzoites 
transform into the inactive bradyzoite form associated with cyst-formation in the 
host musculature and central nervous system (CNS) [22, 23, 24],
Because humans are an intermediate host, the life cycle of T. gondii in humans 
differs from that in its definitive host, the cat. Cats become infected with Toxo­
plasma upon predation and ingestion of cysts in the musculature of their prey. In 
the intestinal tract of feline species, Toxoplasma undergoes both sexual and asex­
ual development and oocysts are shed in feces as early as 3-10 days after ingestion. 
These oocysts are extremely infectious and ingestion of a single oocyst can result 
in infection [24],
T. gondii infection is normally innocuous, manifesting only as general malaise 
during the acute stage of infection. However, infection becomes a serious threat in 
immunocompromised hosts and in Acquired Immunodeficiency Syndrome (AIDS) 
patients, toxoplasmosis presents as tissue destruction and encephalitis due to rup­
ture of cysts in the musculature and CNS [23]. While current HIV treatment
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has shown success in keeping Toxoplasma at bay, in the underdeveloped world, 
infection remains a vital threat [24],
Toxoplasma can also be transferred congenitally if infection occurs in seronega­
tive pregnant women. As with immunocompromised adults, toxoplasmosis results 
in severe neurological diseases. Affected fetuses show signs of hydrocephalus, chori- 
oretinits, and intracranial calcification. In addition, infected infants will often show 
signs of mental retardation, convulsions, and blindness [23],
Toxoplasma research also has the potential to be applied to a number of other 
intracellular parasites. Toxoplasma has become a model for studying the host- 
pathogen response to other members of the Apicomplexa phylum such as Plas­
modium, and other intracellular parasites including Trypanasomes and Leishma- 
nia; together these parasites affect and kill millions of people worldwide.
2.4.2 Manipulation of Macrophage Signaling by Toxoplasma gondii
In-vivo studies have shown that T. gondii has a preference for infecting cells of the 
innate immune system including M $ ’s and dendritic cells. While this may seem 
paradoxical at first, it is now understood that Toxoplasma does this as a way to 
manipulate the host immune response into a safe reservoir for dissemination and 
replication [26].
Toxoplasma entry into host cells is an active process distinct from host en- 
docytic processes. Studies have shown that T. gondii actively invades and that 
this is dependent on formation of a parasite actin-myosin motor and interactions 
between bridge moieties of the parasite and host cell surfaces [27]. As the para­
site enters, the host membrane is dragged inward to form a specialized vacuole. 
In marked contrast to normal receptor-mediated endocytosis, T. gondii invasion
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forms a paristophorous vacuole (PV) that resists acidification and fusion with host 
lysosomes [26, 27]. This PV is important for recruitment of host organelles, in­
cluding mitochondria and the endoplasmic reticulum, which is thought to aid in 
utilization of host lipids and metabolites [27, 28]. This positioning allows the 
PV to come into close contact with the nucleus and through injection of rhoptry 
proteins, to manipulate host signaling pathways.
Study of these parasite proteins was made possible by identification of three 
parasites lineages. Type I parasites are the most lethal in mice, resulting in death 
before encystment. Type II and III strains on the other hand, are nonlethal and 
establish dormant infection. Further observations that Type I and Type III—  
but not Type II—infection is able to induce high levels of IL-12 led to the use 
of quantitative trait locus mapping and the identification of the rhoptry protein, 
R0P16 [25],
Type I R0P16 is a potent activator of both STAT3 and STAT6, capable of 
directly phosphorylating tyrosine residues. STAT3 is a member of the JAK/STAT 
signaling axis and its activation by Toxoplasma downregulates inflammatory cy­
tokine production and serves as a means to promote parasite persistence [28]. 
Previous work done in the Denkers lab has shown that Type I R0P16 deleted 
strains (AR0P16) deleted strains are unable to sustain STAT3 phosphorylation; 
this sustained STAT3 activation is restored in AROP16 strains complemented with 
Type I R0P16 (AROP16:l) [25].
STAT6 activation as previously discussed, is important in the upregulation of 
Argl and this has been shown to be dependent on Type I ROP16. It is thought 
that activation of Argl confers several benefits to Toxoplasma. First, because both 
iNOS and Argl compete for L-arginine, Argl induction prevents excessive produc-
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tion of microbicidal NO by iNOS. Second, Argl induction produces polyamines 
which are necessary for parasite growth. And third, paradoxically, activation of 
STAT6 may serve as a way to limit parasite replication; Toxoplasma is an arginine 
auxotroph and is dependent on host arginine for its survival. By inducing Argl, 
arginine concentrations are limited in the host cell, thus preventing excess growth 
and host burden by Toxoplasma [25].
While Toxoplasma infection downregulates pro-inflammatory cytokine signal­
ing upon initial infection, eventually T. gondii itself will induce expression as a way 
to promote a protective Thl response. Host cells infected with T. gondii are non- 
responsive to TLR signaling pathways and IFN7 . IFN7  signaling as discussed pre­
viously, is dependent on signaling through the STAT1 transcription factor. While 
it is still unclear how Toxoplasma inhibits STAT1 mediated signaling, T. gondii is 
very effective at silencing this signaling cascade, inhibiting expression from over a 
hundred gamma-activated sequences, including expression of Nos2. TLR signaling 
is also inhibited by T. gondii infection through manipulation of the MAPK and 
NFkB signaling axis. It is still unclear how Toxoplasma blocks late-stage MAPK 
activation and whether nuclear translocation of NFkB is inhibited by Toxoplasma 
infection, but LPS-induced production of TNF and IL-12 is inhibited in T. gondii 
infected cells [26].
I examined the manipulation of M<f> activation pathways by T. gondii using 
RT-qPCR, looking specifically at different markers of CA and AA; while it has been 
shown that Type I infection results in STAT6 activation and induction of Argl, it is 
not known whether T. gondii infection results in an A A phenotype. Using different 
Type II R0P16 mutants, I show that alternative activation of M T’s by Toxoplasma 
is dependent on Type I ROP16 and that pre-infection with Toxoplasma does not
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prevent AA. Furthermore, I show that T. gondii infection upregulates production 
of chemokines CCL17, CCL21, and CCL24. These chemokines are important in 
the recruitment and activation of Th2 effector cells. Altogether, my work indicates 
that in contrast to the classification of T. gondii as a canonical Th1 pathogen, T. 
gondii also induces and promotes a Th2 response upon infection.
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3 Results
IL-4 treatment polarizes M $ ’s to an alternative activation phenotype.
Stimulation of BM -M $’s with IL-4 for six hours resulted in upregulation of the 
alternative activation markers Argl (Fig. 2a), Ym l (Fig. 2b), and FIZZ1 (Fig. 
2c). Co-stimulation of B M -M f’s with IFN7  and LPS (IFN7 /LPS) on the other 
hand resulted in little to no induction of these AA markers.
IFN7 /LPS treatment polarizes M $ ’s to a classically activated pheno­
type.
Stimulation of M<f>s with IFN7 /LPS for six hours increased expression of the classi­
cal activation markers Nos2 (Fig. 3a), and the pro-inflammatory cytokines IL-12 
(Fig. 3b), TNFa (Fig. 3c), and IL-6 (Fig. 3d). IL-4 treatment resulted in 
little to no induction of these CA markers relative to untreated cells.
Plasticity of C A -M $’s
To examine if CA-M $’s could be converted to AA-M4>’s with IL-4 treatment, 
M T’s were co-stimulated with IFN7  and LPS for six hours before incubation with 
IL-4 for different timepoints. Medium pre-treated cells upregulated Argl (Fig. 
4a), Ym l (Fig. 4b), and FIZZ1 (Fig. 4c) in a time-dependent matter when 
stimulated with IL-4.
IL-4 treatment of CA-M $’s also increased Argl expression (Fig. 4a). How­
ever, because TLR signaling can also result in upregulation of Argl, plasticity was 
further examined in the context of Ym l and FIZZ1 induction [29].
Pre-treatment of M $ ’s with IFN7  and LPS downregulates Ym l as shown by 
the decreased Ym l expression relative to medium treated control cells at the 0
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Figure 2: IL-4 treatment alternatively activates M$s.
Quantitative PCR analysis showing expression of (a) Argl, (b) Ym l, and 
(c) FIZZ1 mRNAs (relative to Actin mRNA and medium-treated cells) in total 
RNA extracted from bone marrow derived macrophages treated with IFNy 
(lOOng/mL) and LPS (lOOng/mL) or IL-4 (lOng/mL) for 6 hours. * P<0.05 ; 
**P<0.01; ***P<0.001 (two-tailed Students t-test). Results are representative of 
four (a) and five (b,c) independent experiments; data are represented as mean ±  
SEM.
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Figure 3: IFN7 /LPS treatment classically activates M $ ’s.
Quantitative PCR analysis showing expression of (a) Nos2, (b) IL-12, (c) 
TNFa, and (d) IL-6 mRNAs (relative to Actin mRNA and medium-treated cells) 
in total RNA extracted from B M -M f’s treated with IFN7  (lOOng/mL) and LPS 
(lOOng/mL) or IL-4 (lOng/mL) for 6 hours. * P<0.05 ; **P<0.01; ***P<0.001 
(two-tailed Students t-test). Results are representative of five (a), four (b,c), 
and three (d) independent experiments; data are represented as mean ±  SEM.
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time point (Fig. 4b). While there is a slight increase in Ym l expression with 
IL-4 treatment, the fold increase plateaus around one; this indicates that Ym l 
expression levels however around that of the control population. Therefore, while 
IL-4 treatment may abrogate the inhibitory effects of IFN7  and LPS pre-treatment, 
it is unable to upregulate production of Ym l.
IFN7  and LPS treatment also downregulates FIZZ1 expression. While the pre- 
Classically activated M $ ’s increase FIZZ1 expression within a six hour window of 
IL-4 treatment, inhibition relative to medium pre-treated cells is still observed 
(Fig. 4c). This increase in FIZZ1 expression however, is not sustained. Between 
6 hours and 18 hours post-IL-4 treatment, FIZZ1 expression decreases to levels 
comparable to the control population, indicating that IL-4 treatment is unable 
to induce expression of AA markers. These data suggest that IL-4 treatment is 
unable to skew CA-M $’s to an AA phenotype and that IFN7 /LPS pre-treatment 
inhibits IL-4 signaling over an extended period of time.
However, it is possible that IL-4 treatment attenuates the CA phenotype, con­
verting CA-MT’s to an un-stimulated state. To address this possibility, the effects 
of IL-4 treatment on the expression of the CA markers Nos2 and IL-12 were exam­
ined (Fig. 5). Nos2 expression is sustained in the CA population in the presence 
of IL-4, even slightly increasing between 6 to 18 hours of IL-4 treatment. IL-12 
levels also show little change, slightly increasing with IL-4 stimulation. Whereas 
Nos2 expression is sustained in the absence of IFN7  and LPS, IL-12 expression 
may be attenuated; this is evidenced by the lower levels of IL-12 expression in 
the CA-MT population compared to those observed in Fig. 3b and Fig. 6c.. 
Nonetheless, IL-4 treatment does not decrease expression of the CA markers Nos2 
and IL-12, indicating that the CA phenotype is largely maintained (i.) in the
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absence of continued IFN7  and LPS stimulation and (ii.) in the presence of IL-4.
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Figure 4: CA-M $’s are not polarized to an AA phenotype upon IL-4 treatment.
Quantitative PCR analysis showing expression of (a) Argl, (b) Ym l, and 
c) FIZZ1 mRNAs (relative to Actin mRNA and medium-treated cells) in total 
RNA extracted from BM M fs. M4>s are pre-treated with IFN7  (lOOng/mL) and 
LPS (lOOng/mL) or medium for 6 hours before a second stimulation with IL-4 
(lOng/mL). * P<0.05 ; **P<0.01; ***P<0.001; ****P<0.0001 (2-way ANOVA 
with Sidak Multiple Comparisons correction). Data are representative of 2-5 
independent experiments; data are represented as mean ±  SEM.
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Figure 5: CA-M $’s maintain CA phenotype upon IL-4 treatment.
Quantitative PCR analysis showing expression of (a) Nos2 and (b) IL-12 
mRNAs (relative to Actin mRNA and medium-treated cells) in total RNA 
extracted from B M -M f’s. $ ’s are pre-treated with IFNy (lOOng/mL) and 
LPS (lOOng/mL) or Medium for 6 hours before a second stimulation with IL-4 
(lOng/mL). * P<0.05 ; **P<0.01; ***P<0.001; ****P<0.0001 (2-way ANOVA 
with Sidak Multiple Comparisons correction). IFN7 /LPS pre-treated results are 
representative of 2-3 experiments for (a); and three (0-6h) and one (18h) for (b). 
Medium pre-treated results are representative of 2-5 independent experiments; 
data are represented as mean ±  SEM.
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Plasticity of A A -M f ’s
To examine if A A-MT’s can be converted to CA-MT’s in the presence of IFN7  and 
LPS co-stimulation, M T’s were incubated with IL-4 or medium for 6 hours before 
stimulation with IFN7  and LPS for different timepoints. Medium pre-treated cells 
upregulated both Nos2 and IL-12 in a time-dependent manner (Fig. 6). This is 
mirrored by the increase in Nos2 and IL-12 expression of the IL-4 pre-treated, AA- 
M $ population (Fig. 6a). Notably, IL-4 pre-treated M4>’s were more responsive 
to IFN7 /LPS treatment, expressing higher levels of Nos2 at 3, 6 and 18 hours 
post IL-4 removal relative to medium pre-treated M $ ’s (Fig. 6a). Expression of 
IL-12 was also upregulated in the IL-4 pre-treated population in a time-dependent 
manner with sustained, high levels of expression even after 18 hours of IFN7 /LPS 
treatment (Fig. 6b). These results indicate that A A -M $’s can readily upregulate 
CA markers in response to IFN7 /LPS stimulation and adopt a CA phenotype.
I next examined whether M T’s stimulated with IFN7 /LPS continued to express 
high levels of AA markers, which would indicate the possibility of a hybrid AA- 
CA M$. Alternatively, IFN7 /LPS treatment could abrogate the expression of AA 
markers, skewing the AA-M T’s to a CA phenotype. Within 6 hours of IFN7 /LPS 
treatment, Argl (Fig. 7a), Ym l (Fig. 7b), and FIZZ1 (Fig. 7c) continue to be 
expressed by AA-M T’s. However, between 6 and 18 hours of treatment, expression 
of these A A markers is decreased. Notably, both Ym l and FIZZ1 expression levels 
decrease to levels comparable to those of the medium treated control (Fig. 7b, 
7c). Argl expression, though attenuated, continues to be at levels higher than the 
medium control. This however is paralleled by the medium pre-treated population 
and can be attributed, in part, to TLR signaling. However, another possibility, 
as I discuss later (Fig. 11), is that this decrease in AA marker expression is not
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due to IFN7 /LPS treatment but rather, to the removal of IL-4 signaling. This 
would indicate that expression of Ym l, FIZZ1, and Argl (to a lesser extent) by 
AA-M T’s relies on continuous IL-4 signaling
Nonetheless, A A-MT’s can be readily skewed to a CA phenotype after 18 hours 
of IFN7 /LPS stimulation and this transition occurs without a return to an un­
stimulated state; in the presence of IFN7 /LPS, A A -M $’s begin to upregulate 
expression of CA markers as early as 45 minutes (Fig.5). Coupled with the 
sustained expression of AA markers during this time, these results suggest that 
the transition from an AA to CA phenotype is marked by a hybrid CA-AA M4> 
expressing markers of both CA and AA.
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Figure 6: AA-M<F’s are polarized to a CA phenotype upon IFN7 /LPS treatment.
Quantitative PCR analysis showing expression of (a) Nos2 and (b) IL-12 
mRNAs (relative to Actin mRNA and medium-treated cells) in total RNA ex­
tracted from B M -M f’s. M $ ’s are pre-treated with IL-4 (lOng/mL) or medium for 
6 hours before a second stimulation with IFN7  (lOOng/mL) and LPS (lOOng/mL). 
* P<0 05 • **P<0 OP ***p<0 OOP ****P<0.0001 (2-way ANOVA with Sidak 
Multiple Comparisons correction). IL-4 pre-treated results are representative of 
2-3 independent experiments for (a); two (0-6h) and one (18h) for (b). Medium 
pre-treated results are representative of 2-5 independent experiments, data are 
represented as mean ±  SEM.
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Figure 7: AA-M$s do not maintain AA phenotype upon IFN7 /LPS treatment
Quantitative PCR analysis showing expression of (a) Argl, (b ) Ym l, and 
(c) FIZZ1 mRNAs (relative to Actin mRNA and medium-treated cells) in total 
RNA extracted from BM M fs. M<Fs are pre-treated with IL-4 (lOng/mL) or 
medium for 6 hours before a second stimulation with IFN7  (lOOng/mL) and LPS 
(lOOng/mL). * P<0.05 ; **P<0.01; ***P <0.001; ****P<0.0001 (2-way ANOVA 
with Sidak Multiple Comparisons correction); data are representative of 3-5 
independent experiments. Data are represented as mean ±  SEM.
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Type I, but not Type II, T. gondii infection polarizes M $s to an AA  
phenotype.
Previous work in the Denkers lab has shown that Type I R0P16 is necessary for 
induction of Argl in M T’s [25]. Because high levels of Argl expression are one of 
the hallmarks of AA, I wanted to investigate whether other markers of AA are also 
upregulated, indicating that T. gondii infection skews M<t>’s to an AA phenotype.
M<f>s were infected with either RH— wild type Type I strain—or Pru— a Type 
II strain— in a 3:1 ratio of parasites to M $ for 0, 3, 6, and 18 hours. As expected, 
RH infection resulted in increasing and sustained Argl expression (Fig. 8a). 
Similar increases in two other hallmarks of AA—Ym l (Fig. 8b) and FIZZ1 (Fig. 
7c) — suggest that RH infection skews M$s to an alternative phenotype.
While Pru infection resulted in slight increases in Argl expression 6 hours post­
infection this increase was not sustained. Argl expression levels after 18 hours of 
infection decreased to levels comparable with those of control medium population 
(F ig .8). Similarly, induction of Ym l and FIZZ1 is neither sustained nor shows 
clear increases upon Pru infection. 18 hours post Pru-infection, both Ym l and 
FIZZ1 levels remain comparable to those of the control population. Therefore, 
while RH is able to induce expression of the AA markers Argl, Ym l, and FIZZ1 
and polarize MTs to an AA phenotype, Pru infection does not. These results 
showed that Type I ROP16 is necessary for the induction of Argl, Ym l, and 
FIZZ1.
Although Type II T. gondii strains have previously been reported to induce 
a CA phenotype [30], in my hands both Pru and RH infection result in modest 
increases in Nos2 (Fig. 9a) and IL-12 expression (Fig. 9b); neither RH nor Pru 
infection induced expression of TNFa. In contrast to previous work, RH infection
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results in slightly higher, albeit not signihcant, levels of Nos2 and IL-12 expression 
18 hours post-infection. Notably, M T’s infected with RH also express high levels 
of A A markers while M $ ’s infected with Pru do not (Fig. 8). This would suggest 
again, the possibility that M$s can adopt a hybrid phenotype where both CA and 
AA markers are expressed.
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Figure 8: Type I, but not Type II, T. gondii infection polarizes M<f>’s to an A A 
phenotype.
Quantitative PCR analysis showing expression of (a) Argl, (b ) Ym l, (c) 
FIZZ1 mRNAs (relative to Actin mRNA and medium-treated cells) in total RNA 
extracted from BM-MT’s. MT’s are infected at a 3:1 ratio of parasites to M<P or 
treated with IL-4 (lOng/mL) in a timecourse. *P<0.05 ; **P<0.01; ***P<0.001; 
****P< 0.0001 (2-way ANOVA with Sidak Multiple Comparisons correction). 
Data represent 3-5 independent experiments; data are represented as mean ±  
SEM.
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Figure 9: Type I and Type II T. gondii infection results in low levels of CA 
marker expression.
Quantitative PCR analysis showing expression of a) Nos2, (b ) IL-12, (c) 
TNFa mRNAs (relative to Actin rnRNA and medium-treated cells) in total RNA 
extracted from BM -M $’s. M T’s are infected at a 3:1 ratio of parasites to MT or 
treated with IFN7  (lOOng/mL) and LPS (lOOng/mL) in a timecourse. *P<0.05 
. **p<o.OP ***P<0.00T ****P<0.0001 (2-way ANOVA with Sidak Multiple 
Comparisons correction) Data represent 2-6 independent experiments; data are 
represented as mean ±  SEM.
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T. gondii infection induces expression of the chemokines CCL17, CCL21, 
and CCL24.
Another hallmark of A A is the expression of the selective chemokine CCL17 
[2, 31];. CCL17 or TARC (thymus and activation-regulated chemokine) is a T 
cell-directed CC chemokine that along with other chemokines, including CCL21 
and CCL24, plays an important role in promoting a Th2 response [32], CCL21, or 
SLC (secondary lymphoid organ), functions to recruit APCs and T-cells together 
to promote T-cell activation [33]. CCL24 (eotaxin-2), originally identified as a 
chemotactic factor for eosinophils, is a potent recruiter of other components of the 
innate immune system including neutrophils, basophils, and macrophages [34].
To examine the effect of Toxoplasma infection on induction of these chemotac­
tic factors, M $ ’s were infected in a 3:1 ratio of parasites to M $ for six hours and 
expression levels were compared to IL-4 treated M f ’s. As shown in Fig. 10a, 
RH and Type II AROP16 parasites complemented with Type I ROP16 (A16 2:1) 
induced expression of CCL17 to levels comparable with IL-4 treatment. Pru, Type 
II ROP16 complemented knockouts (A16 2:2), and ROP16 knockouts (A16) in­
stead induced significantly lower levels of CCL17 (Fig. 10a). RH infection also 
induced significantly higher levels of CCL21 and CCL24 relative to Pru, A16 2:2, 
and A16 parasites (Fig. 10b, 10c). Given these observations, it was clear that 
while Type I ROP16 induced higher levels of CCL17, CCL21, and CCL24 expres­
sion upon infection, induction was not entirely dependent on ROP16; infection 
with A 16 parasites resulted in low levels of expression.
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Figure 10: Induction of chemokines CCL17, CCL21, and CCL24 is enhanced by 
Type I ROP16.
Quantitative PCR analysis showing expression of (a) CCL17, (b ) CCL21, 
(c) CCL24 mRNAs (relative to Actin mRNA and medium-treated cells) in total 
RNA extracted from BM-MT’s. M T’s are infected at a 3:1 ratio of parasites 
to M $ or treated with IL-4 (lOng/mL) for six hours. *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001 (1-way ANOVA with Tukeys Multiple Corrections 
Test); Black *s denote significance vs. RH infection; Red *s denote significance 
relative to A16 2:1 infection; Blue *s denote significance vs. IL-4 treatment. Data 
shown represent 2-5 independent experiments; data are represented as mean ±  
SEM.
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Effects of T. gondii pre-infection on AA polarization.
To examine whether T. gondii pre-infection attenuates or enhances AA polariza­
tion with IL-4 treatment, M T’s were infected in a 3:1 ratio of parasites to M$ 
for six hours before stimulation with IFN7 /LPS, IL-4, or medium alone for an 
additional 18 hours. Expression of the AA markers Argl, Ym l, and FIZZ1 were 
assessed relative to IFN7 /LPS, IL-4, and medium pre-treatment as controls.
Beginning with Fig. 11c, we can see that RH and A16 2:1 induce sustained 
expression of Argl up to 24 hours after the initiation of infection. Additionally, 
both Pru and A16 2:2 are able to induce and sustain Argl induction— albeit at a 
lower level— and that A16 and IFN7 /LPS pre-treated populations also express low 
levels of Argl. The induction of Argl with Pru, A16 2:2, and A16 pre-infection as 
well as with IFN7 /LPS pre-treatment is somewhat expected because TLR ligands 
can induce expression of Argl [29]. It is interesting to note that the IL-4 pre-treated 
population does not sustain Argl expression when IL-4 stimulation is removed; 
namely, that despite pre-treatment with IL-4 for 6 hours, during the subsequent 
18 hours in medium, Argl expression is lost.
This same reduction in AA marker expression is seen in Fig. I l f  where the 
IL-4 pre-treated population was unable to sustain Ym l expression in the absence 
of IL-4 stimulation. Both RH and A16 2:1 however, maintained expression of 
Ym l while Pru, A16 2:2, and A16 pre-infection did not. These results coincide 
with those depicted in Fig. 8 where Pru infection was unable to induce AA 
marker expression. In Fig. H i however, T. gondii pre-infection and IL-4 pre­
treatment both conferred sustained levels of FIZZ1 expression. As with the other 
AA markers, both RH and A16 2:1 pre-infection induced higher levels of FIZZ1 
expression consistent with the role of Type I ROP16 in activation of STAT6 and
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polarization of M T’s to an AA phenotype. Pru, A16 2:2, and A16 pre-infection 
also induced expression of FIZZ1 24 hours after the initiation of infection, again at 
a lower level compared to RH and A16 2:1 (Fig. Hi). Notably, FIZZ1 expression 
did not require continued IL-4 stimulation, as evidenced by the sustained high 
levels of FIZZ1 expression with IL-4 pre-treatment (Fig. lli).
T. gondii pre-infection, regardless of strain, did not inhibit AA polarization 
upon IL-4 stimulation (Fig. lib , lie , llh ). In Fig. lib , we can see that 
in fact, Toxoplasma pre-infected populations showed higher expression of Argl 
and Ym l compared to the IL-4 and medium pre-treated. Pre-treatment of M $ ’s 
with Toxoplasma also resulted in high induction of FIZZ1 upon IL-4 secondary 
treatment (Fig. 11c). Secondary IFNy/LPS however, was able to attenuate 
expression of the AA markers Argl (Fig. 11a), Ym l (Fig. lib ), and FIZZ1 
(Fig. 11c). We can see that secondary IFN7 /LPS treatment led to several fold 
lower expression of Argl in the RH pre-treated population (Fig. 11a) compared 
to its respective population in Fig. 11c. This decrease in AA marker expression 
is also seen in Fig. lid  and Fig. l lg  in the expression of Ym l and FIZZ1 
respectively. Expression of these AA markers is similarly decreased in the Type 
II pre-infection populations (Fig. 11a, lid , llg ). These results indicate that 
while IL-4 was able to polarize T. gondii pre-infected M T’s to an AA phenotype, 
IFN7 /LPS secondary treatment also downregulated the expression of AA markers, 
attenuating Type I ROP16-mediated alternative activation.
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Figure 11: T. gondii pre-infection does not prevent AA of M<f>s.
Quantitative PCR analysis showing expression of (a-c) Argl, (d -f) Ym l, 
and (g-i) FIZZ1 mRNAS (relative to Actin mRNA and medium-treated cells) in 
total RNA extracted from BM -M $’s. M<I>’s are infected in a 3:1 parasite to M<!> 
ratio or treated with IFNy (lOOng/mL) and LPS (lOOng/mL), IL-4 (lOng/mL), 
or medium for 6 hours before treatment with IFN7 /LPS, IL-4, or medium for an 
additional 18 hours. Data are represented as means of one experiment.
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Effects of T. gondii pre-infection on CA polarization.
M $’s from the same experiment (Fig. 12) were further examined for the effects 
of T. gondii pre-infection on CA polarization (Fig. 12). Without any secondary 
cytokine treatment, T. gondii induced expression of Nos2 (Fig. 12c) and IL-12 
(Fig. 12i) but not TNFa (Fig. 12i). Markedly, RH pre-infection induced lower 
levels of Nos2 (Fig. 12c) and IL-12 (Fig. 12i) relative to pre-infection with the 
Type II strains.
Relative to secondary treatment with medium, expression of Nos2 (Fig. 12a) 
and IL-12 (Fig. 12g) were upregulated by several fold in T. gondii pre-infected 
M T’s. TNFa expression was also upregulated with IFNy/LPS treatment although 
at levels lower than that of IL-4 pre-treated M $ ’s (Fig. 12d). RH and A16 2:1 
pre-infection attenuated expression of Nos2 (Fig. 12a) and TNFa (Fig. 12g) 
relative to IL-4 pre-treated cells. Therefore, while MT’s alternatively activated by 
IL-4 stimulation readily express high levels of CA markers following IFN7 /LPS 
treatment, expression of CA markers is attenuated by infection with parasites 
expressing Type I R0P16.
Pre-infection with Pru and A 16 parasites showed attenuation of Nos2 (Fig. 
12a) and TNFa (Fig. 12d) expression relative to IL-4 pre-treated cells (Fig. 
12d). However, these populations also expressed comparatively higher levels of 
IL-12 relative to the IL-4 pre-treated population(Fig. 12g). This is further 
confounded by the high expression of Nos2 by A 16 2:2 pre-infected MT’s (Fig. 
12a). Together these results implicate virulence factors distinct from ROP16 in 
the interference of IFN7 /LPS signaling.
IL-4 secondary treatment had little effect on the expression of CA markers by 
T. gondii pre-infection, paralleling the IFN7 /LPS pre-treated population (Fig.
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12b, 12e, 12h); expression of Nos2, TNFa, and IL-12 were at levels comparable 
to those of secondary medium treated populations (Fig. 12c, 12f, 12i).
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Figure 12: Pre-infection with Type I ROP16 expressing T. gondii attenuates CA 
polarization.
Quantitative PCR analysis showing expression of (a-c) Argl, (d-f) Ym l, 
and (g-i) FIZZ1 mRNAS (relative to Actin mRNA and medium treated cells) in 
total RNA extracted from BM-MT’s. M T’s are infected in a 3:1 parasite to M<f> 
ratio or treated with IFN7  (lOOng/mL) and LPS (lOOng/mL), IL-4 (lOng/mL), 
or medium for 6 hours before treatment with IFN7 /LPS, IL-4, or medium for an 
additional 18 hours. Data are represented as means of one experiment.
45
4 Discussion
M T’s play a pivotal role in both innate and adaptive immunity. As professional 
phagocytes, M $ ’s play the essential role of clearing infection and activating the 
adaptive immune response through their APC functions. Furthermore, M $ ’s are 
able to detect and respond to changes in their microenvironment through the 
expression of diverse cell surface receptors. Therefore, while the ability to mount 
a tailored immune response is a hallmark of the adaptive immune response, M T’s 
too possess a remarkable adaptability through their ability to reshape their genetic 
landscape in response to different signals.
I examined the plasticity of activated M $ ’s through analysis of gene expression 
changes in response to different polarizing stimuli. Expression changes do not 
necessarily reflect the activity of the gene product; nor do they address factors 
such as degradation rates of mRNA transcripts or of protein stability. However, 
expression of a gene does show how the activity of transcription factors, of genetic 
remodeling, and of other factors can influence expression of genes in response to 
different signals.
Previous work has established antagonism between the IL-4-STAT6 axis, which 
drives AA, and the IFN7 /STAT 1 and NF-k,B signaling axes [3]. This antagonism 
is due in part to the Transactivator Domain (TAD) of STAT6, which binds to 
and sequesters shared transcriptional activators from STATl-activated sequences 
[35]. Recent work has also begun to shed light on the role of SOCS (Suppressor 
of Cytokine Signaling) proteins, though their role in determining M<F activation 
is still controversial because Type I and Type II Interferons, IL-4, and IL-13 have 
all been reported to induce expression of SOCS-1 [36, 37]. To further complicate
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this model, SOCS-1 has been reported to antagonize M<f> responses to IFN7  [37] 
and IL-4 [36]. One possible explanation for this apparent paradox is that while 
SOCS-1 can be upregulated in both classical and alternative activation, what may 
determine M<f> phenotype is ultimately the ratio between SOCS-1 and SOCS- 
3: a high ratio of SOCS-1 to SOCS-3 promotes a AA phenotype by activation 
of PI3K; a low ratio of SOCS-1 to SOCS-3, on the other hand, promotes a CA 
phenotype through inhibition of PI3K [38]. While this is may present an appealing 
explanation, further work needs to be done to further establish this proposed model 
[38].
Here I have shown that BM -M $’s activated to a CA phenotype by stimulation 
with IFN7 /LPS are unable to (i.) sustain increased expression of AA markers 
and (ii.) continue to express high levels of CA markers when treated with the 
AA polarizing cytokine IL-4. On the other hand, BM-M4>’s activated to an AA 
phenotype by stimulation with IL-4 readily (i.) upregulate and sustain expression 
of CA markers while (ii.) downregulating expression of AA markers when stim­
ulated with IFN7 /LPS. My findings suggest that AA-MT are more plastic and 
can be readily converted to a CA phenotype. On the other hand, CA-M $’s are 
less plastic and cannot be converted to an A A phenotype upon IL-4 treatment. 
This difference in plasticity is not readily explained by current understandings of 
STAT1-STAT6 antagonism and interactions.
While it is tempting to attribute this conversion entirely to stimulation with 
the CA-polarizing IFN7 /LPS, another possible explanation is that continuous IL-4 
stimulation is needed to maintain an AA phenotype and STAT6 activation. There­
fore, while IFN7 /LPS treatment is able to induce expression of CA markers, the 
decrease in expression of AA markers could be an in vitro artifact. Additionally,
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the inertness of CA-M $’s when stimulated with IL-4 may also be due to positive 
autocrine and paracrine feedback loops from secreted pro-inflammatory cytokines.
Nonetheless, my findings show that this conversion from an AA to CA phe­
notype happens through an intermediate transition state where both CA and AA 
signaling pathways are activated. In other words, rather than proceed through a 
deactivated phenotype, AA-M T’s undergo a hybrid CA-AA phenotype before con­
version into CA-MT’s. It is also possible that due to my experimental methods, 
my RT-qPCR results are not reporting a hybrid phenotype, but rather, the gene 
expression profile of a mixed M<F population. This is certainly possible and further 
studies using flow cytometry, which would allow the phenotype of individual cells 
to be examined, should be undertaken in the future, However, because observation 
of this hybrid phenotype occurs within a short 6 hour window, distinguishing M<F 
phenotypes based on protein biomarkers may be difficult.
Still, I believe my findings support the gradient of M<f> activations proposed by 
Mosser [2], Rather than think of activated M $ ’s as distinct, mutually exclusive 
populations at opposite ends of a linear scale, it is more apt to designate a spectrum 
of M $ activation whereby M T’s are not restricted to expressing exclusively CA 
or AA markers (Fig. 13). This new approach to MT activation addresses issues 
associated with classifying M T’s into activation states based on their expression 
of activation markers. For example, in my hands IFN7 /LPS stimulated Argl 
expression, a hallmark AA marker after 12 hours of stimulation (Fig. 4a), but 
also high levels of Nos2 (Fig. 5a) and IL-12 (Fig. 5b)— hallmark CA markers. 
R would be difficult to designate this population as solely classically activated or 
alternatively activated.
This model of M $ activation is also more conducive to our understanding of
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C A - M $
Figure 13: The Spectrum of M<!> Activation.
the role of M<f>’s in the body. Because M $ ’s are subject to numerous environmen­
tal signals at any given time, it is unlikely that M $ ’s are purely one activation 
phenotype versus another. Tumor associated macrophages (TAM $), for example, 
display characteristics of both regulatory and alternatively activated macrophages 
while MT’s associated with obesity patients have characteristics of both CA and 
AA-M T’s [2],
I further showed that T. gondii infection resulted in induction of Argl, Ym l, 
and FIZZ1 expression, characteristic of AA-M T’s, and that this polarization was 
dependent on expression of Type I ROP16 (Fig. 8). Yet, these infected M T’s
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also expressed low levels of the CA markers Nos2, IL-12, and TNFa (Fig. 9). 
Therefore, rather than characterize Toxoplasma as solely a Thl-inducing pathogen, 
the parasite may more accurately be balancing a Th2 response, protective to the 
parasite, with a Thl response, protective for the host. Therefore, while seemingly 
paradoxical, by infecting M T’s, Toxoplasma situates itself in a uniquely versatile 
position where manipulation of the host immune system can readily be achieved. 
Indeed, parasite infection induced expression of the chemokine CCL17, important 
for the recruitment of Th2 cells. Infection also induced production of CCL24, 
which is a potent eosinophil chemotactic factor. Secretion of these two chemotactic 
factors amplify the Th2 response because eosinophils are important providers of 
IL-4 in the body. While I showed that expression of the hallmark AA markers 
Argl, Ym l, and FIZZ1 (Fig. 8) was dependent on Type I R0P16, induction of 
these chemokines was not. This may indicate a conserved mechanism for inducing 
a Th2 response, independent of ROP16.
Preliminary data also suggest that T. gondii infection does not prevent AA 
of M T’s by IL-4 stimulation; in fact, both Type I and Type II pre-infected M T’s 
showed increased expression of AA markers following IL-4 treatment. Notably, IL- 
4 treatment was not able to downregulate T. gondii induced Nos2, TNFa, or IL-12 
expression (Fig. 12b, 12e, 12h). This parallels the unresponsiveness of CA- 
M T’s to IL-4 stimulation (Fig. 4). Furthermore, my preliminary data shows that 
IFNq/LPS co-stimulation upregulated expression of CA markers, although at lower 
levels compared to uninfected M4>’s. This contradicts the current literature citing 
the inhibition of IFN7  and TLR signaling by Toxoplasma infection. One hypothesis 
is that simultaneous stimulation with IFN7  and LPS is able to synergistically 
override the ability of Toxoplasma to interfere with pro-inflammatory signaling.
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However, another possibility for this observed increase in CA marker expression is 
that upregulation may be reflective of un-infected M<F’s.
Overall, my work lends insight into plasticity of CA and AA M $ ’s. Whereas 
previous work has shown the deactivating effects of IL-10 on pro-inflammatory 
cytokine production, my work shows that IL-4 stimulation is not able to deactivate 
CA-M $’s and skew them to an AA phenotype. On the other hand, AA-M T’s are 
readily converted to a CA phenotype and possess a hybrid AA-CA gene expression 
profile during their transition.
By further understanding the molecular basis of M $ plasticity, we can begin 
to better understand how these activated M<F populations play a role in disease 
[39]. For example, CA-MT’s are generally associated with early stages of cancer, 
possibly due to their production of ROS and RNS which can lead to DNA damage 
[2]. However, as tumor growth proceeds, the M $ phenotypes become more similar 
to those of R-M<f>’s and these TA M $’s secrete factors that modify the tumor 
microenvironment [2, 40]. Furthermore, studies have shown that M T’s can vary in 
phenotype depending on their spatial location [39]. Understanding of how these 
complex groups of M $ activations arise in the tumor microenvironment will further 
our understanding of cancer progression and holds therapeutic potential.
I further showed that T. gondii infection alternatively activates M<F’s and is 
able to induce expression of Th2 promoting chemokines. While expression of these 
chemotactic factors occurs in Type II ROP16 parasites, it is enhanced by Type 
I ROP 16-expressing parasites. Furthermore, I have shown preliminary data that 
indicates T. gondii does not interfere with with AA polarization. These results 
indicate that rather than characterize Toxoplasma as a Thl pathogen, it may be 
more accurate to classify it as a Th2 parasite as well. T. gondii’s preference for
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M<f> invasion may therefore be a way for the parasite to display extreme versatility 
in balancing the host Thl and Th2 response. In light of the proposed spectrum 
of M<E> activations, so too must our understanding and classification of pathogens 
into polarized extremes change to meet this complexity.
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5 Materials and Methods
5.1  M ice
Female C57BL/6 mice, 6-8 weeks old, were purchased from Taconic Farms (Ger­
mantown, NY) and housed under pathogen-free conditions in the Cornell Univer­
sity College of Veterinary Medicine animal facility, an accredited institution by 
the Association for the Assessment and Accreditation of Laboratory Animal Care 
International.
5 .2  Parasites
Tachyzoites were maintained by twice weekly passage on human foreskin fibroblast 
monolayers in DMEM (Life Technologies, Gaithersburg, MD) 1% heat-inactivated 
bovine growth serum (HyClone, Logan, UT), 100 U/mL Penicillin (Life Technolo­
gies) and 0.1 U/mL Streptomycin (Life Technologies).
5 .3  B one m arrow -derived M<£> preparation
Bone Marrow M T’s were flushed from femur and tibia and cultured for 5-6 days 
in DMEM, 9% heat-inactivated bovine growth serum (HyClone, Logan, UT), 100 
U/mL Penicillin (Life Technologies), 0.1 U/mL Streptomycin (Life Technologies), 
30% supernatant from L929 cells as a source of M-CSF. After 5-6 days of culture, 
non-adherent cells were removed, and adherent monolayers were washed and resus­
pended in PBS before plating in DMEM with 1% heat-inactivated bovine growth 
serum, 100 U/mL Penicillin (Life Technologies) and 0.1 U/mL Streptomycin.
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5 .4  M acrophage A ctivation  and C ell Culture
M T’s were plated in the presence of 100ng/mL IFN7  (Peprotech) and 100ng/mL 
LPS (S. minnesota, ultrapure, List Biological Laboratories, Campbell, CA for 
classical activation and IL-4 (Peprotech) at 10ng/mL. Infection was accomplished 
by addition of tachyzoites to MT cultures in a 3:1 ratio of parasites to M T’s. Plates 
were briefly centrifuged (600-1200 x g for 2 minutes to synchronize infection. In 
experiments with multiple treatments, plates were washed two times with PBS 
before secondary cytokine stimulation or parasites were added.
5.5  R everse Transcriptase Q uantitative P olym erase Chain  
R eaction
Total RNA was prepared from cell cultures using the E.Z.N.A. Total RNA Kit 
I (Omega Bio-Tek) with on-column RNAse free DNAse treatment (Omega Bio- 
Tek). RNA was converted to cDNA using qScript cDNA Supermix kits (Quanta 
Biosciences, Gaithersburg, MD). Quantitative PCR was performed and normalized 
to the expression of housekeeping gene Actin using SYBR green chemistry (Quanta 
Biosciences, Gaithersburg, MD) and ABI 7500 fast machine (Life Technologies 
Corporation, Carlsbad, CA). Expression relative to untreated cells was assessed 
using the AACt method.
5 .6  P rim er Sequences
Actin-Forward: TGGAATCCTGTGGCATCCATGAAAC 
Actin-Reverse: TAAAACGCAGCTCAGTAACAGTCCG 
Argl-Forward: AAGAATGGAAGAGTCAGTGTGG
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Arg1-Reverse: GGGAGTGTTGATGTCAGTGTG 
CCL17-Forward:TACCATGAGGTCACTTCAGATGC 
CCL17-Reverse: GCACTCTCGGCCTACATTGG 
CCL21 -Forward:GTGATGGAGGGGGTCAGGA 
CCL21 -Reverse: GGGATGGGACAGCCTAAACT 
CCL24 -Forward:ATTCTGTGACCATCCCCTCAT 
CCL24-Reverse: TGTATGTGCCTCTGAACCCAC 
FIZZ1 -Forward: CCTCCACTGTAACGAAGACTCTC 
FIZZ1 -Reverse: GCAAAGCCACAAGCACACC 
IL-12p40-Forward: GGAAGCACGGCAGCAGAATA 
IL-12p40-Reverse: AACTTGAGGGAGAAGTAGGAATGG 
IL-6-Forward: GAGGATACCACTCCCAACAGACC 
IL-6-Reverse: AAGTGCATCATCGTTGTTCATACA 
Nos2-Forward: AAGCTGATGGTCAAGATCCAG 
Nos2-Reverse: CCACCTCCAGTAGCATGTTG 
TNFa-Forward: CATCTTCTCAAAATTCGAGTGACAA 
TNFa-Reverse: TGGGAGTAGACAAGGTACAACCC 
Ym1 -Forward: ATCTATGCCTTTGCTGGAATGC 
Ym1 -Reverse: TGAATGAATATCTGACGGTTCTGAG
5 .7  Statistics
Statistical analysis was performed as indicated using GraphPad Prism.
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